Navigation Links
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Date:2/2/2012

LANGHORNE, Pennsylvania and OXFORD, England, February 2, 2012 /PRNewswire/ --

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC® for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma. Under the terms of the agreement, EUSA will pay Alizé Pharma an upfront fee, regulatory milestone payments and royalties on future product sales.  

ASPAREC is a recombinant, pegylated Erwinia chrysanthemi-derived asparaginase. It is currently in phase I development for the treatment of ALL in patients with hypersensitivity to standard-of-care E. coli-derived asparaginase therapy, and has been granted orphan status by the US and European regulatory authorities.  Preclinical data indicate that ASPAREC is potentially longer acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.

Commenting on the news, Bryan Morton, President and Chief Executive Officer of EUSA Pharma, said, "We are delighted to reach this agreement with Alizé Pharma.  ASPAREC fits perfectly with EUSA's specialty focus on oncology and orphan diseases, and builds on our established portfolio in the field of acute lymphoblastic leukemia.  This agreement follows the approval last year of EUSA's first internally developed product, and further underlines the company's strategic transition into a fully fledged development as well as commercialization organization."

"This agreement between Alizé Pharma and EUSA Pharma, a worldwide leader in the development and marketing of L-asparaginase products, is excellent news for us, for our investors and for ALL patients," said Alizé Pharma's President and founder, Thierry Abribat. "It validates our medical approach, emphasizes our drug development capabilities, and fits well with our business strategy, which is to establish partnerships with the pharmaceutical industry early in the development of our programs in order to secure both near-term and long-term revenue streams."

About acute lymphoblastic leukemia

Acute lymphoblastic leukemia is the most common form of childhood cancer, with approximately 2,900 patients under the age of 20 diagnosed in the USA each year [1].  It is also one of the most curable forms of cancer, with remission rates in treated children of over 95% and 75 - 85% surviving at least five years without recurrence of leukemia [1].  Treatment involves a number of stages and drugs, and typically includes asparaginase as an essential component of current protocols.  

About asparaginase and ASPAREC

Asparaginase enzymes deplete the level of asparagine in the bloodstream.  Asparagine is essential for cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia.  Asparaginase treatments are derived from bacteria, and approximately 15 - 20% of patients develop hypersensitivity to modern products derived from Escherichia coli, preventing their continued treatment [2].  ASPAREC is a proprietary recombinant, pegylated Erwinia chrysanthemi-derived asparaginase in development for the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived therapies.  Preclinical data indicate ASPAREC is potentially longer acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.  

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care products.  The company has an established commercial infrastructure in the US, a pan-European presence and a wider distribution network in numerous additional territories.  EUSA currently has a total of 10 specialist hospital products, which are sold in over 80 countries globally*.  These include Erwinase®/Erwinaze and Kidrolase® for the treatment of acute lymphoblastic leukemia, Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Collatamp® G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint® for imaging the extent and spread of prostate cancer and Quadramet® for the treatment of pain in patients whose cancer has spread to the bones.  The company also has a number of products in late-stage development.

References

[1] US National Cancer Institute.  Childhood acute lymphoblastic leukemia treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/childALL/HealthProfessional/page1

[2] Raetz EA, Salzer WL.  J Pediatr Oncol 2010:32:554-563.

* Not all products are approved currently for use in the US

Contacts
Bryan Morton    
Chief Executive    
EUSA Pharma    
Tel: +44(0)1865-784255    

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241



'/>"/>
SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
2. CVS/pharmacy Helps Customers Save Time with New Prescription Text Alerts
3. Valeant Pharmaceuticals Acquires Probiotica in Brazil
4. Shylendra Kumar Joins Pharmaceutical eConsulting
5. Worlds Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event
6. Innocoll Enters CollaGUARD® Distribution Partnership With Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany
7. Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
8. Belvidere Pharmacy, Custom Medicine Makers, Moves to New, and Even Better, Home
9. Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
10. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
11. Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):